Loading clinical trials...
Loading clinical trials...
A Phase 2a Multicenter Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Sunitinib Malate Depot Formulation (GB-102) in Subjects With Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO)
Conditions
Interventions
GB-102
Locations
6
United States
Retinal Research Institute
Phoenix, Arizona, United States
Southern Retina
Savannah, Georgia, United States
Eye Care Institute
Louisville, Kentucky, United States
Boston Retina
Boston, Massachusetts, United States
Sierra Eye Associates
Reno, Nevada, United States
Texoma Retina Center
Denison, Texas, United States
Start Date
September 11, 2019
Primary Completion Date
June 5, 2020
Completion Date
June 5, 2020
Last Updated
November 22, 2021
NCT07449936
NCT07449923
NCT07228559
NCT05802329
NCT06781255
NCT06701721
Lead Sponsor
Graybug Vision
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions